Articles

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
DANDU GIRIJA, *AKKIMI PADMA, A.TIRUPATHIREDDY, BASU VENKATESWARA REDDY
Sankar Reddy Institute of Pharmaceutical sciences, Salakalveedu, Bestavaripeta, Prakasam, Andha pradesh, India.

ABSTRACT
The present research work was broadly focused on the estimation of in Lacidipine in bulk and pharmaceutical dosage form by using two UV spectrophotometric methods like Zero order spectroscopy (Method-1), and first order derivative spectroscopy (Method-2). The solvent employed for the two methods was methanol and absorption maximum was found to be 284nm, and 277nm respectively. The developed methods showed linearity sin the range between 20-100µg/ml. The correlation co-efficient was ≥ 0.999. The precision (%RSD) for all the two methods was found to be ≤2. The accuracy was performed by spiking standard drug at 50,100 and 150% of the test concentration and the values obtained were within the limits. The assay for the formulation was found to be within limits. All the results were satisfactory the developed methods were linear, accurate, reproducible and robust. 

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
SRI HARSHA AYYAGARI.*HARI PRIYA MULLAMURI, SOWMYA  BYREDDY,   DURGA PRASAD T. S.
Sri Padmavathi School of pharmacy, Jawaharlal Nehru Technological University, Anantapuram, Andhra Pradesh, India.

ABSTRACT
Glanzmann's Thrombasthenia (GT) is a rare, autosomal recessive bleeding disorder characterized by prolonged bleeding time and impairment in aggregation of platelets and impairment in clot retraction. The physiological defect includes impairment of glycoprotein receptor’s (GPIIb/IIIa complex) present on platelet membrane which mediates platelet aggregation through fibrinogen binding. Purpose of this study is to get  all of us know about this rare condition. A 16-year old female patient presented with repeated episodes of menstrual bleeding since 4years. She was a k/c/o Glanzmann's thrombasthenia. She was treated with antifibrinolytics, IV fluids and then discharged. Early diagnosis and proper supportive care are the measures for prognosis of Glanzmann’s thrombasthenia.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
ASHIKA RANJANI. M*, SAHITHI GOUD. B, AMATUL WADOOD SUMAYYA, SYEDA NABILA FIRDOUS, AMATUL ALI SAMEERA
Dept. of Pharmacy Practice
Sree Dattha Institute of Pharmacy, Jawaharlal Nehru Technological University (Hyderabad)
Sheriguda (V), Ibrahimpatnam (M), Ranga Reddy (Dist), Telangana, India

ABSTRACT
AIMS AND OBJECTIVES: Our aim was to evaluate the clinical use of Antihypertensive drugs in patients with chronic Kidney disease at a tertiary care teaching hospital.

METHOD: An observational, prospective cohort study was conducted at a tertiary care teaching hospital in Hyderabad, T.S, India. A total of 184 patients from the inpatient department of nephrology Department at  Gleneagles Global Hospitals, Bairamalguda, LB Nagar, Hyderabad. All information significant to the study was collected from the case records and discussions conducted with the in-patients and bystanders during ward rounds, with the support of a physician, which were analyzed by SPSS software. Moreover, daily follow-ups were conducted to assemble data on amendment in therapy, add-on therapy, and clinical improvement.

RESULTS: The Mean Age was 59.29 years and the standard deviation was 1.116 of the population, 60% were smokers and 40% were alcoholics. The most commonly used Class of anti-hypertensive drugs are Calcium channel blockers with percentage of 64.13%, Diuretics with percentage of 57.60%, β blockers with percentage of 43.47%. Whereas most commonly used Calcium channel blockers are Amlodipine with percentage of 52%, and Cilindipine with percentage of 9.10%.Diuretics are are Furosemide with percentage of 36.90% and Toresemide 11.40%. Most commonly used Adenergic Antagonist are in β Blockers are Metoprolol with percentage of 31.50%, In α blockers are prazosin with percentage of 26%, In α+β blocker are Carvedilol with percentage of 8.60%. Most commonly used ARB’s are Telmisartan with percentage of 6.50%, and ACE’s are Ramipril with percentage of 1%. Most commonly used central sympatholytics are Clonidine with percentage of 18.40%, Vasodilators are Minoxidil with percentage of 1%. Medication adherence have been done, In which patients with High Adherence are with percentage of 16.21%, Medium Adherence are with percentage of 45.94%, Low Adherence are with percentage of 37%. This is done by Morisky medication adherence scale 8.

CONCLUSION: We have concluded that the CCB’s, diuretics and β-blockers are the most commonly used anti-hypertensive classes in hypertensive patients with CKD. Use of anti-hypertensives in CKD patients does not deviate from the guidelines laid down by NKF KDOQI guidelines. The patients should be educated about the rational use of drugs to decrease medication adherence.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Aliyu Hamidu Ahmed¹, Yusuf Ibrahim Alkali^2
1Department of Pharmacognosy and Ethno pharmacy, Faculty of Pharmaceutical Sciences
Usmanu Danfodiyo University, Sokoto- Nigeria
²Department of Pharmacology and Toxicology, Usmanu Danfodiyo University, Sokoto- Nigeria.

ABSTRACT
Pharmacokinetics and toxicity profile along with efficacy are the major determinants for successful drug development. This study was carried out to determine the pharmacokinetic profile, potential biological activities and toxicity of diospyrin, lupeol and plumbagin using in silico approaches. The Swiss ADME tool was used to calculate the molecular properties of the ligands based on Lipinski’s rule of five (5).All ligands in the present study satisfied the rule. Using the Swiss ADME tool, the pharmacokinetic profile of the compounds was evaluated. Protox-II server was used to predict the organ toxicities and toxicological end points of the ligands and their LD50. Plumbagin is found to have both mutagenicity and carcinogenicity. Lupeol and diospyrin are reported to be immunotoxic. Lupeol has LD50 of 2000mg/kg. Diospyrin and plumbagin have 16mg/kg. Swiss target prediction server was used to identify the various potential target. The target prediction suggests that plumbagin and lupeol have high preference for Microtubule-associated protein tau (MAPT). The best target for diospyrin was Aurora kinase A. Molecular docking study was conducted using AutoDock vina in The Python Prescription (PyRx) 0.8 virtual screening tool.  Plumbagin and lupeol were docked against Microtubule associated protein tau. The dockings scores based on binding energy were; plumbagin -33.8 (kcal/mole) and lupeol -44.7 (kcal/mole). Diospyrin showed a binding energy of -10.7 (kcal/mole) against Aurora A kinase. Results in this study suggest that diospyrin may serve as an important aurora kinase inhibitor while lupeol and plumbagin may be useful in treatment of Alzheimer’s disease.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Asha K Rajan, Vedha pal Jeyamani.S*, Kaviya U, Merlin Joan , Lavanya. R
Department of Pharmacy Practice,
Jaya College of Paramedical Sciences,
College of Pharmacy, Thiruninravur,
Chennai, Tamil Nadu, India.

ABSTRACT: 
Pituitary adenomas are slowly progressive and usually benign type of tumors which may induce a poor quality of life of patients due to progressive loss of vision over time by compression of optic nerves, cavernous sinus, optic chiasm. Its therapy generally involves differential diagnosis with an MRI of Brain and surgical option with radiation therapy. Here with we present a case of 48 year old women who had undergone microscopic transnasal transphenorbital excision of tumor two years ago of pituitary macroadenoma. She was not on any chemotherapy which led to a recurrence of her tumor. Presently her MRI scan and histopathologic reports confirms the diagnosis of Pituitary macroadenoma which was effectively treated surgically and put up on Dihydroartemisnin, a derivative of Artemether which has similar cytotoxic properties as that of artemether.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Ubaid Tariq¹, MohdMazhar*²
Delhi Pharmaceutical Science and Research University,
M.B. Road, Saket , New Delhi, 110017, India

ABSTRACT:
Three-dimensional (3D) printing is a manufacturing method in which objects are made by fusing or depositing materials in successive layers laid down under computer control. These objects can be of almost any shape or geometry and are produced from a 3D model as defined in a computer-aided design (CAD). Since the inception of 3D printing in 1984 it has evolved immensely and has been used in many fields including medicine, architecture and more recently in pharmaceutical manufacturing. From lab grown organs to drug delivery devices, 3D printing is advancing rapidly and in future course of time it is going to transform and change the way we live and work.

3D printing in pharmaceuticals has been used to produce many novel dosage forms like microcapsules, Complex Drug-Release Profiles, nano-suspensions, and multilayered drug delivery devices. From industrial point of view it also offers important advantages like, cost-effectiveness, increased productivity, democratization of design and manufacturing, and enhanced collaboration.Keeping in view the recent approval given by USFDA to the first 3D printed antiepileptic drug the focus has now shifted to the personalized medicine as it offers an important benefit to patients who need medications that have narrow therapeutic indices or a higher predilection to be influenced by genetic polymorphisms. 3D printer is now seen as a valuable, efficient and economical tool to manufacture individualized medications, tailored to specific patients based on their needs and thereby change the future of pharmacy practice in general and pharmaceutical care in particular.

{ DOWNLOAD AS PDF }

ABOUT AUTHOR
AK MOHIUDDIN
Faculty of Pharmacy, World University of Bangladesh
Dhanmondi, Dhaka, Bangladesh

ABSTRACT
Pharmacoeconomics has been characterized as the depiction and examination of the cost of medication treatment to healthcare frameworks and society. All the more explicitly, pharmacoeconomic look into is the way toward recognizing, estimating, and contrasting the costs, dangers, and advantages of programs, services, or treatments and figuring out which elective delivers the best wellbeing result for the asset contributed. This data can help clinical chiefs in picking the most cost-effective treatment alternatives. Pharmacoeconomics is a division of results examine that can be utilized to measure the estimation of pharmaceutical care items and services. Pharmaceutical care has been characterized as the mindful arrangement of medication treatment for the reasons for accomplishing unequivocal results.

Figure 1. Graphical Extract

Materials and Methods:
Research conducted a year-round comprehensive literature search, which included technical newsletters, newspapers journals, and many other sources. The present study was started from the beginning of 2018. PubMed, ALTAVISTA, Embase, Scopus, Web of Science, and the Cochrane Central Register of was thoroughly searched. The keywords were used to search for different publishers’ journals like Elsevier, Springer, Willey Online Library, Wolters Kluwer were extensively followed. Medicine and technical experts, pharma company representatives, hospital nurses and chemists were given their valuable suggestions. Projections were based on estimates of drug and therapy related cost, cost of being ill and hospitalization and cost of well-being. Pharmacists role in allied areas of cost calculation and minimizing through ADR management, prevent disease and hospitalization and drug selection were given the highest priority.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
A. PADMA¹*, D. GIRIJA², A. THIRUPATHIREDDY³, B. VENKATESWARAREDDY^4
1Department of Pharmaceutical Analysis, Sankar Reddy Institute of Pharmaceutical sciences, Salakalveedu(v), Bestavaripeta(M), Prakasam (Dist) Andhra Pradesh, India
²Department of Pharmaceutical Analysis, Sankar Reddy Institute of Pharmaceutical sciences, Salakalveedu(v), Bestavaripeta(M), Prakasam (Dist) Andhra Pradesh, India
³Department of Pharmaceutics, Sankar Reddy Institute of Pharmaceutical sciences, Salakalveedu(v), Bestavaripeta(M),Prakasam(Dist) Andhra Pradesh, India
⁴Department of Pharmaceutics, Sankar Reddy Institute of Pharmaceutical sciences, Salakalveedu(v), Bestavaripeta(M), Prakasam(Dist) Andhra Pradesh, India

ABSTRACT
The present research work deals with the development  and validation of  stability indicating RP-HPLC method for the simultaneous estimation of Aceclofenac and Drotaverin.HCl in bulk and formulation. Chromatographic separation was achieved on ODS HG-5 RP   C18(250 X 4.6 mm, 5 µm) using the mobile phase consisting of Acetonitrile and1% triethylamine (TEA) in the ratio of 90:10 pH  2.16 adjusted with Ortho phosphoric acid. The mobile phase was pumped at a flow rate of 1.0 mL/min and UV detection was observed  at 224 nm. The retention time was found to be 3.57 min for Aceclofenac and 6.15 min for Drotaverin.HCl. The linearity concentrations are obtained from in the range of 30-70 µg/ml for Aceclofenac and 24-56 µg/ml for Drotaverin.HCl respectively with correlation coefficient was 0.999 and 0.998. The proposed method was found to be simple, accurate, precise and reproducible and developed method can be suggest to routine quality control analysis for simultaneous estimation of Aceclofenac and Drotaverin.HCl in pharmaceutical dosage forms.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Mir Sahidul Ali*¹, Souvik Mukherjee², Subhajit Makar², Gargi Pal³
*¹Department of Chemical and Polymer Engineering,
Tripura University, Suryamaninagar, Tripura, India
²Centre for Pharmaceutical Sciences &
Natural Products, School of Basic and Applied Sciences,
Central University of Punjab, Bathinda, Punjab, India
³Department of Pharmaceutical Sciences and Technology,
NSHM Knowledge Campus, Kolkata, India.

ABSTRACT:
Cucurbitacins which are structurally unlike triterpenes found in the members of Cucurbitaceae and several other plant families possess immense pharmacological activity. This diverse group of compounds may substantiate to be important lead molecules for the treatment of cancer. Research focused on these unattended medicinal compound can prove the significance and explore the hidden potential to cure various diseases. These compounds shows their proposed mode of action, probable molecular targets and have future aspects of their use as a medicinal agent. This review is aimed to provide the chemical nature and medicinal property of cucurbitacins.